160 related articles for article (PubMed ID: 30124353)
1. Imatinib trough levels: a potential biomarker to predict cytogenetic and molecular response in newly diagnosed patients with chronic myeloid leukemia.
Natarajan H; Kumar L; Bakhshi S; Sharma A; Velpandian T; Kabra M; Gogia A; Ranjan Biswas N; Gupta YK
Leuk Lymphoma; 2019 Feb; 60(2):418-425. PubMed ID: 30124353
[TBL] [Abstract][Full Text] [Related]
2. Influence of MDR1 and CYP3A5 genetic polymorphisms on trough levels and therapeutic response of imatinib in newly diagnosed patients with chronic myeloid leukemia.
Harivenkatesh N; Kumar L; Bakhshi S; Sharma A; Kabra M; Velpandian T; Gogia A; Shastri SS; Biswas NR; Gupta YK
Pharmacol Res; 2017 Jun; 120():138-145. PubMed ID: 28330783
[TBL] [Abstract][Full Text] [Related]
3. Do polymorphisms in MDR1 and CYP3A5 genes influence the risk of cytogenetic relapse in patients with chronic myeloid leukemia on imatinib therapy?
Harivenkatesh N; Kumar L; Bakhshi S; Sharma A; Kabra M; Velpandian T; Gogia A; Shastri SS; Gupta YK
Leuk Lymphoma; 2017 Sep; 58(9):1-9. PubMed ID: 28367681
[TBL] [Abstract][Full Text] [Related]
4. [Comparison of the efficacy and safety of Chinese generic imatinib and branded imatinib in patients with chronic myeloid leukemia in consideration of demographic characteristics].
Dou XL; Yu L; Qin YZ; Shi HX; Lai YY; Hou Y; Huang XJ; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2019 Nov; 40(11):924-931. PubMed ID: 31856442
[No Abstract] [Full Text] [Related]
5. A study to explore the correlation of ABCB1, ABCG2, OCT1 genetic polymorphisms and trough level concentration with imatinib mesylate-induced thrombocytopenia in chronic myeloid leukemia patients.
Francis J; Dubashi B; Sundaram R; Pradhan SC; Chandrasekaran A
Cancer Chemother Pharmacol; 2015 Dec; 76(6):1185-9. PubMed ID: 26546461
[TBL] [Abstract][Full Text] [Related]
6. [Analysis of correlation between plasma trough level and response of generic imatinib in the treatment of Chinese patients with chronic myeloid leukemia].
You JH; Chen J; Zhou L; Du SH; Lu HY; Sun SJ; Li JM; Shen ZX
Zhonghua Xue Ye Xue Za Zhi; 2019 Nov; 40(11):939-942. PubMed ID: 31856444
[No Abstract] [Full Text] [Related]
7. Effects of Trough Concentration and Solute Carrier Polymorphisms on Imatinib Efficacy in Chinese Patients with Chronic Myeloid Leukemia.
Wang Q; Jiang ZP; Zeng J; Zhu Y; Cai HL; Xiang DX; He Q; Shi XL; Zhong AN; Zhao XL; Xu P
J Pharm Pharm Sci; 2020; 23(1):1-9. PubMed ID: 32027818
[TBL] [Abstract][Full Text] [Related]
8. Generic imatinib in the treatment of chronic myeloid leukemia: two years' experience in Latvia.
Lejniece S; Udre I; Rivkina A
Exp Oncol; 2017 Jul; 39(2):151-154. PubMed ID: 29483494
[TBL] [Abstract][Full Text] [Related]
9. Serial monitoring of BCR-ABL transcripts in chronic myelogenous leukemia (CML) treated with imatinib mesylate.
Hardling M; Wei Y; Palmqvist L; Swolin B; Stockelberg D; Gustavsson B; Ekeland-Sjöberg K; Wadenvik H; Ricksten A
Med Oncol; 2004; 21(4):349-58. PubMed ID: 15579919
[TBL] [Abstract][Full Text] [Related]
10. Genetic variations of hOCT1 gene and CYP3A4/A5 genes and their association with imatinib response in Chronic Myeloid Leukemia.
Vaidya S; Ghosh K; Shanmukhaiah C; Vundinti BR
Eur J Pharmacol; 2015 Oct; 765():124-30. PubMed ID: 26300393
[TBL] [Abstract][Full Text] [Related]
11. Pattern of chronic myeloid leukemia in the imatinib era in a Sub-Saharan African setting.
Faye BF; Dieng N; Seck M; Gadji M; Gueye YB; Sy D; Toure SA; Sall A; Toure AO; Dieye TN; Diop S
Ann Hematol; 2016 Oct; 95(10):1603-10. PubMed ID: 27370991
[TBL] [Abstract][Full Text] [Related]
12. Trough concentration and ABCG2 polymorphism are better to predict imatinib response in chronic myeloid leukemia: a meta-analysis.
Jiang ZP; Zhao XL; Takahashi N; Angelini S; Dubashi B; Sun L; Xu P
Pharmacogenomics; 2017 Jan; 18(1):35-56. PubMed ID: 27991849
[TBL] [Abstract][Full Text] [Related]
13. Influence of CYP3A5*3 and ABCB1 C3435T on clinical outcomes and trough plasma concentrations of imatinib in Nigerians with chronic myeloid leukaemia.
Adeagbo BA; Bolaji OO; Olugbade TA; Durosinmi MA; Bolarinwa RA; Masimirembwa C
J Clin Pharm Ther; 2016 Oct; 41(5):546-51. PubMed ID: 27426203
[TBL] [Abstract][Full Text] [Related]
14. The predictive value of early molecular response in chronic myeloid leukaemia patients treated with imatinib in a single real-world medical centre in a developing country.
Bee PC; Sekaran V; Ng RR; Kweh TY; Gan GG
Singapore Med J; 2017 Mar; 58(3):150-154. PubMed ID: 27029807
[TBL] [Abstract][Full Text] [Related]
15. Imatinib mesylate in chronic myeloid leukemia: frontline treatment and long-term outcomes.
Stagno F; Stella S; Spitaleri A; Pennisi MS; Di Raimondo F; Vigneri P
Expert Rev Anticancer Ther; 2016; 16(3):273-8. PubMed ID: 26852913
[TBL] [Abstract][Full Text] [Related]
16. Dose modification of imatinib by monitoring the level of BCR-ABL transcript in chronic myelogenous leukemia.
Ishikawa I; Kato C; Harigae H; Sugawara T; Tomiya Y; Yamada M; Ishizawa K; Kameoka J; Miyamura K; Sasaki T
Tohoku J Exp Med; 2006 Dec; 210(4):355-63. PubMed ID: 17146202
[TBL] [Abstract][Full Text] [Related]
17. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia.
Picard S; Titier K; Etienne G; Teilhet E; Ducint D; Bernard MA; Lassalle R; Marit G; Reiffers J; Begaud B; Moore N; Molimard M; Mahon FX
Blood; 2007 Apr; 109(8):3496-9. PubMed ID: 17192396
[TBL] [Abstract][Full Text] [Related]
18. Molecular Response in Patients with Chronic Myeloid Leukemia Treated with Imatinib - Single Centre Experience.
Pavkovic M; Angelkovic R; Popova-Simjanovska M; Genadieva-Stavric S; Cevreska L; Stojanovic A
Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2015; 36(2):179-86. PubMed ID: 27442383
[TBL] [Abstract][Full Text] [Related]
19. Imatinib-treated chronic myeloid leukemia patients with discordant response between cytogenetic and molecular tests at 3 and 6 month time-points have a reduced probability of subsequent optimal response.
Bonifacio M; Binotto G; Maino E; Calistri E; Marin L; Scaffidi L; Frison L; De Marchi F; Krampera M; Semenzato G; Fanin R; Ambrosetti A; Tiribelli M;
Haematologica; 2015 Aug; 100(8):e299-301. PubMed ID: 25820333
[No Abstract] [Full Text] [Related]
20. Clonal Evolution and Blast Crisis Correlate with Enhanced Proteolytic Activity of Separase in BCR-ABL b3a2 Fusion Type CML under Imatinib Therapy.
Haaß W; Kleiner H; Weiß C; Haferlach C; Schlegelberger B; Müller MC; Hehlmann R; Hofmann WK; Fabarius A; Seifarth W; ;
PLoS One; 2015; 10(6):e0129648. PubMed ID: 26087013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
